Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial-Reference-Cited by-同舟云学术

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Published:2014-01 Issue:1 Volume:15 Page:48-58
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

O'Brien Susan,Furman Richard R,Coutre Steven E,Sharman Jeff P,Burger Jan A,Blum Kristie A,Grant Barbara,Richards Donald A,Coleman Morton,Wierda William G,Jones Jeffrey A,Zhao Weiqiang,Heerema Nyla A,Johnson Amy J,Izumi Raquel,Hamdy Ahmed,Chang Betty Y,Graef Thorsten,Clow Fong,Buggy Joseph J,James Danelle F,Byrd John C

Publisher

Elsevier BV

Subject

Oncology

Reference35 articles.

1. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma;Davis;Nature,2010

2. The future of B-cell lymphoma therapy: the B-cell receptor and its downstream pathways;Kenkre;Curr Hematol Malig Rep,2012

3. Targeting B-cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies;Wiestner;J Clin Oncol,2013

4. Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma;Gururajan;J Immunol,2006

5. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB;Rushworth;Cell Signal,2013

Cited by 422 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive Characterization of BTK Inhibitor Specificity, Potency, and Biological Effects: Insights into Covalent and Non-covalent Mechanistic Signatures;2024-09-08

2. Ibrutinib and venetoclax in combination for chronic lymphocytic leukemia: synergy in practice;Blood Neoplasia;2024-09

3. Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first‐line chemoimmunotherapy;Cancer Medicine;2024-08

4. The kappa/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype;Scientific Reports;2024-06-11

5. SOHO State of the Art Updates and Next Questions | Covalent Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia;Clinical Lymphoma Myeloma and Leukemia;2024-05